CYTEK BIOSCIENCES, INC. (CTKB) Return on equity 2021–2025
CYTEK BIOSCIENCES, INC. (CTKB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-19.5%FY2025 · since FY2021: 0.7% → -19.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -19.5% | -17.9 pp |
| FY2024 | -1.5% | +1.6 pp |
| FY2023 | -3.1% | -3.7 pp |
| FY2022 | 0.6% | -0.2 pp |
| FY2021 | 0.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CTKB financial trends
CTKB RevenueCTKB Net incomeCTKB Net marginCTKB Gross profitCTKB Gross marginCTKB Operating incomeCTKB Operating marginCTKB Operating cash flowCTKB Free cash flowCTKB Capital expendituresCTKB Stock buybacksCTKB Dividends paidCTKB Total assetsCTKB Total liabilitiesCTKB Shareholders’ equityCTKB overview →